Dendreon Gains After Aetna Expands Coverage of Provenge

Dendreon Corp., maker of the prostate cancer drug Provenge, gained after insurer Aetna Inc. said it will cover more patients to receive the therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.